Main glossary
Special | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ALL
O |
---|
Off-labelOff-label use is when a drug is used for something other than for what it was approved. | |
On-label | |
Opportunity costThe cost in terms of the value of the treatment compared to the best alternative option that was not chosen. For example, if the NHS decided to spend
money on a new treatment for a rare disease, an opportunity cost would be that
the money spent on this new treatment could not be spent on anything else. | |
OrphanConditions that only affect a small group of patients. In the European Union (EU), the European Medicines Agency (EMA) defines this as a condition affecting fewer than 1 in 2,000 individuals (European Medicines Agency, 2015). | |
Orphan diseaseAnother term for rare disease. They are conditions that only affect a small group of patients. In the European Union (EU), the European Medicines Agency (EMA) defines this as a condition affecting fewer than 1 in 2,000 individuals (European Medicines Agency, 2015) | |
Orphan drugA medicine developed for a rare disease. | |
OrphanetAn online portal containing information related to rare diseases, orphan drugs, patient organisations, professionals and institutions, research projects, clinical trials, biobanks and expert centres. | |
OutcomeA broad term often used to describe a variety of
results from trials | |
Outcome measuresOutcomes measures are measurements of the effects of a treatment or service. They might include physical measurements - for example measuring blood pressure - or psychological measurements - for example measuring people's sense of well-being. So if someone takes part in research, they may be asked questions or may be asked to have extra tests to assess how well the treatment or service has worked. | |
OutcomesA broad term often used to describe a variety of results from trials | |
Social networks